BioVie Inc., a clinical-stage biotechnology company, is dedicated to the discovery, development, and commercialization of drug therapies in the United States. The company is headquartered in Santa Monica, California.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-22.47M |
| Operating Margin | 0.00% |
| Return on Equity | -150.80% |
| Return on Assets | -79.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.36 |
| Price-to-Book | 1.36 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -11.66 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $8.68M |
| Float | $7.48M |
| % Insiders | 0.49% |
| % Institutions | 22.13% |
Volatility is currently contracting
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) will present results from two Phase 2 trials of its experimental drug bezisterim, in Long COVID and Parkinson's disease, at the American Neurological Association's annual meeting in San Diego. The company said both abstracts were accepted as poster presentations at ANA2026, which runs from October 17 to 20.
CARSON CITY, Nev., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that two abstracts detailing results from the Company's ADDRESS-LC Phase 2 trial in Long COVID, and SUNRISE-PD Phase 2 trial of bezisterim in Parkinson's Disease have been accepted for presentation at ANA2026, the annual meeting of the American Neurological Association.
BioVie Inc. (BIVI) Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets Transcript
BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid Transcript
Conference call scheduled for Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time (ET) Conference call scheduled for Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time (ET)
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) told investors that it is preparing to advance its Phase 3 development program for bezisterim in Parkinson's disease and has requested an End-of-Phase 2 meeting with the US Food and Drug Administration. The company is working with Parkinson's disease clinical development experts to finalize the design of a Phase 3 trial.
Company Corresponded with the FDA on an End of Phase 2 Meeting to Align on Phase 3 trial Design for Evaluation of Bezisterim in Early-stage Parkinson's Disease Company Corresponded with the FDA on an End of Phase 2 Meeting to Align on Phase 3 trial Design for Evaluation of Bezisterim in Early-stage Parkinson's Disease
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that has completed the last on-treatment visit in its Phase 2 ADDRESS-LC clinical trial evaluating bezisterim in adults with Long COVID, with topline results targeted for release before the end of September 2026. The Carson City, Nevada-based clinical-stage company is developing therapies for neurological and neurodegenerative diseases.
CARSON CITY, Nev., Aug. 31, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the last on-treatment visit of its ADDRESS-LC Phase 2 trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID has been completed.
BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BIVI and any ticker you trade — then tracks every position and per-strategy win rate.
